Compare MYSZ & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | JAGX |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.2M |
| IPO Year | 2017 | 2014 |
| Metric | MYSZ | JAGX |
|---|---|---|
| Price | $0.41 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 51.5K | ★ 72.6K |
| Earning Date | 04-15-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.40 | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | $142,000.00 | ★ $11,511,000.00 |
| Revenue This Year | $41.64 | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.33 | $0.22 |
| 52 Week High | $1.38 | $8.00 |
| Indicator | MYSZ | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 23.06 |
| Support Level | $0.38 | $0.96 |
| Resistance Level | $0.67 | $0.99 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 53.57 | 3.91 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.